GW311616A (20-320 μM; 48 hours; U937 cells) treatment inhibits proliferation and induces apoptosis in leukemia cells. GW-311616 (150 μM; U937 cells) treatment can increase the protein expression levels of Bax and decrease the expression of Bcl-2.GW-311616 (150 μM; 48 hours) markedly suppresses NE activity in U937 and K562 cells lines.

GW-311616 has moderate terminal elimination half-life (t1/2) of 1.1 hours and 1.5 hours for dog (2 mg/kg, oral), rat (2 mg/kg, oral), respectively.GW-311616 (2 mg/kg;?oral administration) rapidly abolishes the circulation of neutrophil elastase (NE) in dogs, while >90% inhibition is maintained for 4 days.?This prolonged effect is independent to be due to penetration of neutrophils in bone marrow by orally administrated GW-311616.